Mobile

A Cancer Research UK randomised phase II trial of ATN-224 (copper binding agent) in combination with exemestane versus exemestane alone in post-menopausal women with recurrent or advanced, oestrogen a...

Mise à jour : Il y a 5 ans
Référence : EUCTR2007-005752-16

A Cancer Research UK randomised phase II trial of ATN-224 (copper binding agent) in combination with exemestane versus exemestane alone in post-menopausal women with recurrent or advanced, oestrogen and/or progesterone receptor positive breast cancer

Femme Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

1. Efficacy Compare progression-free survival of ATN-224 in combination with exemestane versus exemestane alone, in post-menopausal women with recurrent or advanced, oestrogen and/or progesterone receptor positive breast cancer. 2. Safety Establish the safety of ATN-224 in combination with exemestane in this patient population.

Critère d'inclusion

  • recurrent or advanced oestrogen and/or progesterone receptor positive breast cancer

Liens